Introduction {#tca13003-sec-0001}
============

Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related morbidity and mortality both worldwide and in China.[1](#tca13003-bib-0001){ref-type="ref"}, [2](#tca13003-bib-0002){ref-type="ref"} Improved understanding of the molecular changes that drive tumor progression has revolutionized the clinical management of NSCLC. EGFR‐tyrosine kinase inhibitors (TKIs) have shown promising results in NSCLC patients with *EGFR*‐positive mutations;[3](#tca13003-bib-0003){ref-type="ref"} however, approximately 20--30% of patients harboring *EGFR*‐activating mutations demonstrate a poor response to EGFR‐TKIs, which indicates a risk of primary resistance and the likelihood that alternative determining factors conferring sensitivity exist.[4](#tca13003-bib-0004){ref-type="ref"} We report a case of an advanced NSCLC patient with intrinsic EGFR‐TKI resistance who achieved disease‐free survival (DFS) of 24 months and overall survival (OS) of 30 months after salvage treatment of chemotherapy combined with anti‐angiogenesis.

Case report {#tca13003-sec-0002}
-----------

In August 2015, a 63‐year‐old Chinese man with a heavy smoking history (60 cigarettes/day for approximately 40 years) was admitted to our hospital. Computed tomography (CT) showed a mass in the right lung and possible metastases in the mediastinal lymph nodes (Fig [1](#tca13003-fig-0001){ref-type="fig"}a). Cranial magnetic resonance imaging, abdominal CT, and bone scans were found to be normal. On 22 October 2015, the patient underwent right middle lobectomy with systematic lymphadenectomy. Pathological analysis revealed a poorly differentiated pulmonary adenocarcinoma (pT2bN2M0, stage IIIa) (Fig [2](#tca13003-fig-0002){ref-type="fig"}a,b). An *EGFR* mutation (L858R) was reported (Fig [3](#tca13003-fig-0003){ref-type="fig"}a).

![Thoracic computed tomography (CT) imaging shows the tumor mass and metastases after various treatments. (**a**) Before surgery, a mass in the right middle lung and possible lymph node metastases in the mediastinal seven region were observed on CT. (**b**) Two months after surgery, CT imaging showed multi‐metastases in the bilateral lungs and mediastinal lymph nodes. (**c**) After one month of gefitinib treatment, CT imaging showed progressive disease (PD). (**d**) After six cycles of chemotherapy, CT imaging showed a complete response (CR). (**e**) CR status at the last follow‐up on 5 June 2018. (**f**) The timeline of different treatments.](TCA-10-1023-g001){#tca13003-fig-0001}

![Representative examples of hematoxylin and eosin (HE) and immunohistochemistry findings. (**a**) Surgical samples confirmed adenocarcinoma with a mass predominant pattern according to typical HE morphology (200×). (**b**) Ki‐67 positive expression (100×). (**c**) High vascular endothelial growth factor (VEGF) expression in tumor tissues (200×). (**d**) High VEGF receptor 2 expression in tumor cells and vascular endothelial cells (200×) (\* shows the small vessel).](TCA-10-1023-g002){#tca13003-fig-0002}

![Detection of driver genes using surgical tumor samples by real time‐PCR and fluorescence in situ hybridization (FISH). The red arrow indicates the positive curve. (**a**) First time detection of *EGFR* showed an exon 21 L858R mutation. (**b**) After gefitinib was administered, secondary analysis showed an L858R mutation and (**c**) *ROS1* fusion. (**d**) *EGFR* T790M and (**e**) *KRAS* were negative. (**f**) FISH analysis for *ROS1.* Several split signals and isolated green signals indicated *ROS1* rearrangement. The distribution of *ROS1* FISH--positive events was 27.1%.](TCA-10-1023-g003){#tca13003-fig-0003}

On 22 December 2015, a CT scan showed new multi‐metastases (Fig [1](#tca13003-fig-0001){ref-type="fig"}b) and gefitinib was administered.[3](#tca13003-bib-0003){ref-type="ref"}, [4](#tca13003-bib-0004){ref-type="ref"} Re‐evaluation demonstrated progressive disease (according to Response Evaluation Criteria In Solid Tumors 1.1) (Fig [1](#tca13003-fig-0001){ref-type="fig"}c). The patient showed primary resistance to gefitinib and refused re‐biopsy. Real‐time (RT)‐PCR (ARMS, Amoy Diagnostics, Xiamen, China) was performed a second time using the surgical samples, and of the six driver genes (*EGFR*, *ROS1*, *KRAS*, *ALK*, *BRAF* and *PIK3CA*) tested, L858R mutation was confirmed and *ROS1* fusion was found (Fig [3](#tca13003-fig-0003){ref-type="fig"}b‐e). Fluorescence in situ hybridization analysis (ZytoLight, ZytoVision GmbH, Bremerhaven, Germany) also indicated *ROS1* rearrangement (Fig [3](#tca13003-fig-0003){ref-type="fig"}f).

ROS1 inhibitors were not prescribed for this patient because they were unavailable in China in January 2016.[5](#tca13003-bib-0005){ref-type="ref"} From January to March 2016, doublet chemotherapy (pemetrexed and cisplatin) plus rh‐Endostatin (Endostar) was administered for two cycles. The therapeutic evaluation was a partial response. The patient was then administered an additional four cycles with the same agents. Imaging demonstrated a complete response (CR) (Fig [1](#tca13003-fig-0001){ref-type="fig"}d). Pemetrexed maintenance was administered for another two cycles until September 2016. The patient then refused further maintenance therapy. At his last follow‐up in June 2018, the patient had maintained a CR (Fig [1](#tca13003-fig-0001){ref-type="fig"}e), with DFS of 24 months and OS of 30 months (Fig [1](#tca13003-fig-0001){ref-type="fig"}f). The toxicities experienced were mainly grade 2 hematologic and gastrointestinal.

Discussion {#tca13003-sec-0003}
==========

Only 1--2% of patients with NSCLC have *ROS1* fusion,[6](#tca13003-bib-0006){ref-type="ref"} and patients who harbor both *EGFR* mutation and *ROS1* rearrangement are extremely rare. Few investigations have focused on the combination of *EGFR* mutation and other gene‐driven activation because of the low incidence. The clinical‐pathological characteristics and the response to EGFR‐TKIs of such patients with multiple mutations remain controversial.[7](#tca13003-bib-0007){ref-type="ref"} To our knowledge, this is the first case to report simultaneous L858R mutation and *ROS1* rearrangement detected in a single NSCLC patient with intrinsic gefitinib resistance.

Mechanisms of EGFR‐TKI resistance are known to be highly heterogenous and are mainly focused on acquired resistance (Table [1](#tca13003-tbl-0001){ref-type="table"}).[8](#tca13003-bib-0008){ref-type="ref"}, [9](#tca13003-bib-0009){ref-type="ref"}, [10](#tca13003-bib-0010){ref-type="ref"}, [11](#tca13003-bib-0011){ref-type="ref"}, [12](#tca13003-bib-0012){ref-type="ref"}, [13](#tca13003-bib-0013){ref-type="ref"}, [14](#tca13003-bib-0014){ref-type="ref"} However, the mechanism of primary resistance to EGFR‐TKIs is still poorly understood. Recent studies have indicated that multiple resistance factors can be induced simultaneously in a single cancer. Examples of these processes include the co‐existence of *ALK* amplification and gatekeeper mutations causing resistance to ALK inhibitors[15](#tca13003-bib-0015){ref-type="ref"} *MET* mutation and activation of the EGFR pathway simultaneously conferring resistance to MET‐TKIs[16](#tca13003-bib-0016){ref-type="ref"} and activation of bypass signaling resulting in resistance in lung cancer cells harboring *ROS1* fusions.[17](#tca13003-bib-0017){ref-type="ref"} These findings, taken together with our case, suggest that co‐activation of other oncogenic signal pathways might result in uncontrolled proliferation or survival in lung cancers, and then confer intrinsic EGFR‐TKI resistance.

###### 

Major mechanisms of EGFR‐tyrosine kinase inhibitor resistance

  Mechanism                           Acquired Resistance
  ----------------------------------- -------------------------------------------------------------------------------
  Modification of target gene         *EGFR* T790M mutation[8](#tca13003-bib-0008){ref-type="ref"}
  Activation of alternative pathway   *c‐Met* amplification[9](#tca13003-bib-0009){ref-type="ref"}
                                      *HGF* ^10^
                                      *HER2* [11](#tca13003-bib-0011){ref-type="ref"}
                                      *BRAF* [12](#tca13003-bib-0012){ref-type="ref"}
  Alteration of downstream            *PTEN* loss[13](#tca13003-bib-0013){ref-type="ref"}
                                      *PIK3CA* mutation[14](#tca13003-bib-0014){ref-type="ref"}
                                      *KRAS* activation[12](#tca13003-bib-0012){ref-type="ref"}
  Others                              Epithelial to mesenchymal transition[14](#tca13003-bib-0014){ref-type="ref"}
                                      Small cell lung cancer transformation[14](#tca13003-bib-0014){ref-type="ref"}

The identification of resistance mechanisms is essential to develop strategies to overcome resistance. Current approaches to combat resistance include salvage of irreversible EGFR‐TKIs, and EGFR‐TKIs combined with drugs targeting other activation pathways. In this case, chemotherapy combined with Endostar showed a durable and satisfactory therapeutic effect and was well tolerated with little toxicity. Chemotherapy should be strongly considered for patients with EGFR‐TKI primary resistance. Moreover, angiogenesis plays a critical role in solid tumor survival and invasion. Endostar has been demonstrated to downregulate expression of vascular endothelial growth factors (VEGFs) and VEGF receptors (VEGFRs) to inhibit tumor angiogenesis and block VEGF‐C signaling to inhibit tumor lymphangiogenesis.[18](#tca13003-bib-0018){ref-type="ref"} In our patient, VEGF and VEGFR2 were strongly expressed in the tumor tissues (Fig [2](#tca13003-fig-0002){ref-type="fig"}c,d), and this might be the reason why this patient showed a positive response to the anti‐angiogenic agent combined with chemotherapy.

The primary resistance mechanisms to EGFR‐TKIs are still not fully understood. In our report, *EGFR* mutation and *ROS1* fusion were found to co‐exist in a heavy smoking NSCLC patient. The co‐activation of different signal pathways might result in EGFR‐TKI primary resistance. Chemotherapy could be a potential option to combat intrinsic EGFR‐TKI resistance, and Endostar might enhance the effectiveness. However, it was not possible to evaluate the response to ROS1 inhibitors in our case because crizotinib or other inhibitors were unavailable. Further studies are required to verify these findings and to explore the underlying mechanisms.
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